Vor Biopharma (VOR) Cash from Operations (2020 - 2026)
Vor Biopharma (VOR) reported Cash from Operations of 38246000.0 for Q1 2026, down 23.11% year-over-year from 49742536.88 in Q1 2025, and down 67.74% on a QoQ basis from 22801000.0 in Q4 2025.
Vor Biopharma (VOR) has 7 years of Cash from Operations data on file, last reported at 38246000.0 in Q1 2026.
- Quarterly Cash from Operations fell 23.11% year-over-year to 38246000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 149893000.0 (down 49.5% YoY) and the FY2025 annual result came in at 142713000.0, down 43.2% from the prior year.
- Cash from Operations retreated to 38246000.0 in Q1 2026 per VOR's latest filing, from 22801000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 18346000.0 in Q4 2022 and bottomed at 53662000.0 in Q3 2025.
- The 5-year median for Cash from Operations is 24100000.0 (2023), against an average of 27415000.0.
- The widest annual swing landed in 2024, when Cash from Operations climbed 16.54%; it then slumped 130.46% in 2025.
- Tracing VOR's Cash from Operations over 5 years: stood at 18346000.0 in 2022, then plunged by 30.96% to 24026000.0 in 2023, then retreated by 0.15% to 24063000.0 in 2024, then rose by 5.24% to 22801000.0 in 2025, then tumbled by 67.74% to 38246000.0 in 2026.
- Per Business Quant, the three latest VOR Cash from Operations figures stand at 38246000.0 (Q1 2026), 22801000.0 (Q4 2025), and 53662000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -38.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.25 Mn |
| Mar 31, 2026 | -38.25 Mn |
| Dec 31, 2025 | -22.80 Mn |
| Dec 31, 2025 | -22.80 Mn |
| Sep 30, 2025 | -53.66 Mn |
| Sep 30, 2025 | -53.66 Mn |
| Jun 30, 2025 | -35.18 Mn |
| Jun 30, 2025 | -35.18 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Mar 31, 2025 | -31.07 Mn |
| Dec 31, 2024 | -24.06 Mn |
| Dec 31, 2024 | -24.06 Mn |
| Sep 30, 2024 | -23.29 Mn |
| Sep 30, 2024 | -23.29 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -30.47 Mn |
| Mar 31, 2024 | -30.47 Mn |
| Dec 31, 2023 | -24.03 Mn |
| Dec 31, 2023 | -24.03 Mn |
| Sep 30, 2023 | -27.90 Mn |
| Sep 30, 2023 | -27.90 Mn |
| Jun 30, 2023 | -24.10 Mn |
| Jun 30, 2023 | -24.10 Mn |
| Mar 31, 2023 | -24.27 Mn |
| Mar 31, 2023 | -24.27 Mn |
| Dec 31, 2022 | -18.35 Mn |
| Dec 31, 2022 | -18.35 Mn |
| Sep 30, 2022 | -18.90 Mn |
| Sep 30, 2022 | -18.90 Mn |
| Jun 30, 2022 | -24.99 Mn |
| Jun 30, 2022 | -24.99 Mn |
| Mar 31, 2022 | -22.90 Mn |
| Mar 31, 2022 | -22.90 Mn |
| Dec 31, 2021 | -17.59 Mn |
| Dec 31, 2021 | -17.59 Mn |
| Sep 30, 2021 | -17.34 Mn |
| Sep 30, 2021 | -17.34 Mn |
| Jun 30, 2021 | -16.57 Mn |
| Jun 30, 2021 | -16.57 Mn |
| Mar 31, 2021 | -17.65 Mn |
| Mar 31, 2021 | -17.65 Mn |
| Dec 31, 2020 | -13.63 Mn |
| Dec 31, 2020 | -13.63 Mn |
| Sep 30, 2020 | -8.25 Mn |
| Sep 30, 2020 | -8.25 Mn |
| Jun 30, 2020 | -8.33 Mn |
| Jun 30, 2020 | -8.33 Mn |
| Mar 31, 2020 | -6.09 Mn |
| Mar 31, 2020 | -6.09 Mn |